Table 1 Characteristics of the included studies for osteoarthritis of knee and/or hip
Study, year | Treatment (daily dose) | Participants randomized (n) | Treatment duration (weeks) | Symptom duration (year) | Mean age (year) | Female (%) | OA grade | Joint | Pain outcome extracted | Timepoint extracted (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|
Glucosamine vs placebo | ||||||||||
 Noack 1994 [21] | G(1500 mg)/placebo | 126/126 | 1–4 | 2.00–10.00 | 55.00 | 60 | I–III | Knee | Lequesne global scale | 4 |
 Houpt 1999 [22] | G(1500 mg)/placebo | 58/60 | 1–8 | 8.30 | 64.46 | 62 | NA | Knee | WOMAC | 12 |
 Reginster 2001 [23] | G(1500 mg)/placebo | 106/106 | 1–144 | 7.80 | 65.75 | 76 | II–III | Knee | WOMAC | 144 |
 Pavelka 2002 [24] | G(1500 mg)/placebo | 101/101 | 1–144 | 10.55 | 62.35 | 79 | II–III | Knee | WOMAC | 144 |
 Braham 2003 [25] | G(1500 mg)/placebo | 24/22 | 1–12 | 12.98 | 42.65 | 28 | I–III | Knee | KPS | 12 |
 McAlinton 2004 [26] | G(1500 mg)/placebo | 101/104 | 1–12 | NA | > 65.00 | 64 | NA | Knee | WOMAC | 12 |
 Cibere 2004 [27] | G(1500 mg)/placebo | 71/66 | 1–24 | 1.60 | 64.48 | 56 | ≥ 2 | Knee | WOMAC | 24 |
 Usha 2004 [28] | G(1500 mg)/placebo | 30/28 | 1–12 | 3.05 | 51.03 | NA | I–III | Knee | VAS | 12 |
 Clegg 2006 [29] | G(1500 mg)/placebo | 317/313 | 1–24 | 9.95 | 58.40 | 63 | II–III | Knee | WOMAC | 24 |
 Herrero-Beaumont 2007 [30] | G(1500 mg)/placebo | 106/104 | 1–12 | 7.30 | 63.94 | 93 | II–III | Knee | WOMAC | 24 |
 Rozendaal 2008 [31] | G(1500 mg)/placebo | 111/111 | 1–12 | 11.70 | 63.40 | 69 | > 2 | Hip | WOMAC | 96 |
 Giordano 2009 [32] | G(1500 mg)/placebo | 30/30 | 1–12 | 6.30 | 57.65 | 70 | I–III | Knee | WOMAC | 24 |
 Fransen 2014 [33] | G(1500 mg)/placebo | 152/151 | 1–48 | > 2.00 | 60.90 | 83 | NA | Knee | WOMAC | 96 |
 Kwoh 2014 [34] | G(1501 mg)/placebo | 98/103 | 1–12 | NA | 52.23 | 49 | 0–4 | Knee | WOMAC | 24 |
Chondroitin vs Placebo | ||||||||||
 Bucsi 1998 [35] | C(1200 mg)/placebo | 39/46 | 1–12 | > 0.50 | 59.95 | 60 | I–III | Knee | VAS | 24 |
 Bourgeois 1998 [36] | C(1200 mg)/placebo | 83/44 | 1–13 | NA | 63.35 | 76 | I–III | Knee | VAS | 13 |
 Uebelhart 1998 [37] | C(1200 mg)/placebo | 23/23 | 1–48 | NA | 58.50 | 52 | I–III | Knee | VAS | 48 |
 Mazieres 2001 [38] | C(1200 mg)/placebo | 63/67 | 1–12 | NA | 67.09 | 75 | II–III | Knee | Pain at rest | 12 |
 Uebelhart 2004 [39] | C(1200 mg)/placebo | 54/56 | 1–12 | NA | 63.45 | 81 | I–III | Knee | Husskisson visual analogue score for pain | 12 |
 Michel 2005 [40] | C(1200 mg)/placebo | 150/150 | 1–96 | NA | 62.80 | 51 | I–III | Knee | WOMAC | 96 |
 Clegg 2006 [29] | C(1200 mg)/placebo | 318/313 | 1–24 | 9.60 | 58.20 | 64 | II–III | Knee | WOMAC | 24 |
 Mazieres 2006 [41] | C(1200 mg)/placebo | 153/154 | 1–24 | 6.40 | 66.00 | 70 | II–III | Knee | Pain at rest | 24 |
 Kahan 2009 [42] | C(1200 mg)/placebo | 309/313 | 1–12 | 6.30 | 62.30 | 68 | I–III | Knee/hip | WOMAC | 12 |
 Wildi 2011 [43] | C(800 mg)/placebo | 35/34 | 1–48 | > 0.50 | 62.26 | 59 | I–III | Knee | WOMAC | 48 |
 Zegels 2013 [7] | C(1200 mg)/placebo | 236/117 | 1–12 | NA | 65.17 | 65 | NA | Knee | Global pain | 12 |
 Fransen 2014 [33] | C(800 mg)/placebo | 151/151 | 1–48 | > 2.00 | 60.05 | 83 | NA | Knee | WOMAC | 96 |
Glucosamine + Chondroitin vs Placebo | ||||||||||
 Clegg 2006 [29] | G + C(1500 + 1200 mg)/placebo | 317/313 | 1–24 | 9.80 | 58.40 | 63 | II–III | Knee | WOMAC | 24 |
 Fransen 2014 [33] | G + C(1500 + 800 mg)/placebo | 151/151 | 1–48 | > 2.00 | 60.65 | 85 | NA | Knee | WOMAC | 96 |
 Lugo 2016 [44] | G + C(1500 + 1200 mg)/placebo | 65/58 | 1–12 | NA | 52.84 | 54 | II–III | Knee | WOMAC | 24 |
 Roman-Blas 2017 [11] | G + C(1500 + 1200 mg)/placebo | 80/78 | 1–24 | 6.20 | 65.99 | 84 | II–III | Knee | Global pain | 24 |